Tempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trial

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

TPST

0.00
  • Tempest Therapeutics entered a development collaboration with Senlang Biotechnology to advance TPST-4003, an in vivo CAR-T candidate.
  • Senlang will run a first-in-human investigator-initiated trial in China in about 10 patients with myasthenia gravis or multiple sclerosis.
  • First patient dosing is expected in Q4 2026; initial safety and pharmacodynamic readouts are expected in H1 2027.
  • Senlang received an exclusive option to negotiate a China license for TPST-4003.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210700PRIMZONEFULLFEED9765173) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.